Kreiner, Frederik F
Novo Nordisk (Denmark)
2 papers on CoChatORCID 0000-0001-8296-453X
Most cited papers
- Verified
Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: A randomised, double-blind, placebo-controlled, phase 2 trial
von Herrath, M., Bain, S. C., Bode, B., Clausen, J. O., Coppieters, K., Gaysina, L., Gumprecht, J., Hansen, T. K., Mathieu, C., Morales, C., et al. (2021) · The Lancet Diabetes & Endocrinology
Diabetes and associated disordersPancreatic function and diabetes
Cited by 186
- Verified
Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity
Friedrichsen, M. H., Endahl, L., Kreiner, F. F., Goldwater, R., Kankam, M., Toubro, S., & Nygård, S. B. (2023) · Molecular Metabolism
Pharmacology and Obesity TreatmentDiabetes Treatment and Management
Cited by 46
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free